Dr. John Cush RheumNow
3 years 11 months ago
Urinary Biomarkers in Lupus
Dr.Cush interviews Dr. Fava about Abstract 536 at #ACR22. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
https://t.co/3IfPdTMufb https://t.co/XVECG9mJri
The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?
Despite the fact that polymyalgia rheumatica is the most prevalent inflammatory rheumatic disease in those over 65 years of age, progress in its diagnosis, monitoring and management have failed to garner momentum in decades past.
However, ACR22 has fostered significant promise for its future.
It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle.
I loved the city, but not the convention center (not easy to navigate).
Dr. John Cush RheumNow
3 years 11 months ago
Social Media in Academic Rheumatology
Dr. Kathryn Dao and Jorena Lim discuss the impact of social media in rheumatology. @KDAO2011
https://t.co/a6yoH745Ap https://t.co/RioB7n9fWZ
Dr. John Cush RheumNow
3 years 11 months ago
Dual target blockade may be better than one in SLE
Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22.
https://t.co/20MGDHBLT1 https://t.co/4IcBKn1IKg
Dr. John Cush RheumNow
3 years 11 months ago
Repetitive Testing of Anti-dsDNA Antibodies May Predict Flares in SLE
Dr. Sheila Reyes ( @RHEUMarampa ) summarizes abstract #0327 presented during the poster session at #ACR22.
https://t.co/kSFfyRIQXZ https://t.co/bVTE9VsFmC
Dr. John Cush RheumNow
3 years 11 months ago
Poor Medication Adherence in SLE and How to Improve It
Dr. Janet Pope ( @Janetbirdope) discusses three abstracts presented at #ACR22.
https://t.co/AWxj4fsTkt https://t.co/Lol1zG7C0q
Dr. John Cush RheumNow
3 years 11 months ago
2022 ACR/EULAR Classification Criteria for GCA
Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA.
https://t.co/w7NE2Wpm95 https://t.co/vB94wS7ONF
Dr. John Cush RheumNow
3 years 11 months ago
To Beta Block or Not in GCA & Large Vessel Vasculitis
Dr. Harkins ( @DrTrishHarkins) discusses abstract 0477 presented at #ACR22.
Abstract 0477: Can Beta-blockers Prevent Aortic Dilation in Patients w/ Giant Cell Arteritis & Large Vessel Vasculitis?
https://t.co/cwA1Z5XrQr https://t.co/QGSS6RUBn3
Dr. John Cush RheumNow
3 years 11 months ago
Avoid Abatacept in RA patients with a history of cancer?
Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22.
https://t.co/t8hun1qfnJ https://t.co/UpuWkk7k3x
Dr. John Cush RheumNow
3 years 11 months ago
Professor Georg Schett, MD (University of Erlangen-Nuremberg) presents his novel study of CAR-T cells therapy in Lupus - A MUST look! #ACR22
ACR 2022: CAR-T Cell Treatment of Refractory SLE | VuMedi https://t.co/cpJShTvQDy via @vumedi
